Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Outstanding (Weighted Average) (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $99.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) fell 0.9% year-over-year to $99.5 million, compared with a TTM value of $99.5 million through Dec 2025, down 0.9%, and an annual FY2025 reading of $99.5 million, down 0.9% over the prior year.
  • Shares Outstanding (Weighted Average) was $99.5 million for Q4 2025 at Neurocrine Biosciences, roughly flat from $99.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $101.1 million in Q3 2024 and bottomed at $94.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 4 years is $98.2 million, with a median of $99.0 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Weighted Average) grew 3.49% in 2024, then fell 1.79% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $94.7 million in 2021, then increased by 3.17% to $97.7 million in 2023, then rose by 2.76% to $100.4 million in 2024, then fell by 0.9% to $99.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for NBIX at $99.5 million in Q4 2025, $99.4 million in Q3 2025, and $99.0 million in Q2 2025.